SCHEMBL5017934

SCHEMBL5017934

COc1c(C(=O)O)c(C)cc2c3ccccc3n(Cc3ccccc3)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 1/20 0.51
ALDH1A1 P00352 3/20 0.48
GAA P10253 3/20 0.48
MAPT P10636 3/20 0.48
PKM P14618 2/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
PLA2G2A P14555 6/20 0.47
PLA2G1B P04054 1/20 0.47
CYP19A1 P11511 1/20 0.46
EDNRB P24530 1/20 0.45
EDNRA P25101 1/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
KDM4E B2RXH2 3/20 0.45
HSD17B10 Q99714 1/20 0.45
FABP4 P15090 1/20 0.44
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5018089 0.78 CCR2 (0.50) CCR2ALDH1A1GAAMAPTPKM
SCHEMBL8387973 0.77 MEN1 (0.53) ALDH1A1GAAMAPTKMT2AMEN1
SCHEMBL612585 0.76 POLB (0.62) CCR2ALDH1A1GAAMAPTPKM
SCHEMBL9538638 0.75 CCR2 (0.77) CCR2ALDH1A1MAPTKMT2AMEN1
SCHEMBL8387525 0.74 PLA2G2A (0.49) CCR2ALDH1A1GAAMAPTPKM
SCHEMBL9056067 0.73 MAPT (0.46) ALDH1A1GAAMAPTPKMKMT2A
SCHEMBL9056374 0.73 ELANE (0.47) CCR2ALDH1A1GAAMAPTPKM
SCHEMBL4363430 0.72 PLA2G2A (0.79) ALDH1A1GAAMAPTPKMKMT2A
SCHEMBL2215283 0.72 CYP19A1 (0.49) CCR2ALDH1A1GAAMAPTKMT2A
SCHEMBL8390306 0.72 MAPT (0.52) ALDH1A1GAAMAPTPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LTC4S, TSLP, GPR119 CCR2 78/4885ALDH1A1 2372/4885GAA 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.